Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LPPC-Q7
- Development stage
- Preclinical
- Lead developer
- National Yang Ming Chiao Tung University
- Modality
- Peptides, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
LPPC-Q7 is an experimental nanotherapeutic consisting of the anticancer peptide Q7 encapsulated within a Lipo-PEG-PEI complex (LPPC). The Q7 peptide is a 15-amino acid sequence (EQQQQQQPQNRRFRE) that functions by suppressing the expression of 24-dehydrocholesterol reductase (DHCR24), a critical enzyme in the cholesterol biosynthesis pathway. This inhibition leads to the disruption of cholesterol-rich lipid rafts and caveolae, subsequently attenuating the PI3K/AKT/mTOR signaling pathway. The LPPC nanocarrier provides protection against proteolytic degradation and facilitates efficient intracellular delivery of the peptide. In preclinical models of endometrial cancer, LPPC-Q7 has demonstrated the ability to inhibit cell proliferation, migration, and invasion, while inducing apoptosis. It is also being investigated in combination with doxorubicin (LPPC-Q7-DOX) to enhance therapeutic efficacy and suppress exosome-mediated metastasis.
- Other names
- Lipo-PEG-PEI complex-Q7
02
Targets
AKT (RAC-alpha serine/threonine-protein kinase)CAV1 (Caveolin-1)DHCR24 (3β-hydroxysterol Δ24-reductase)
Beyond the preview
Go deeper on LPPC-Q7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LPPC-Q7.